ANI Pharmaceuticals (ANIP) News Today

BNP Paribas Financial Markets lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 106.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,739 shares of the specialty pharmac

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has been assigned an average rating of "Buy" from the four research firms that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that

Inspire Investing LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,520 shares of the specialty pharmaceutical company's stock

Global Alpha Capital Management Ltd. lessened its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 32.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 390,750 sh

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $64.91, for a total value of $16,227.50. Following the completion of the transaction, the vice president now directly owns 58,981 shares in the company, valued at approximately $3,828,456.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Lisanti Capital Growth LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,085 shares of the special

Wakefield Asset Management LLLP bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 14,163 shares of the specialty pharmaceutical company's stock, valued at approxima

Allspring Global Investments Holdings LLC boosted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 287.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,277 shares of the specialty pharmaceutical company's stock afte

ANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 3% Following Insider Selling

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The sale was disclosed in a legal filing with the SEC, which is available at this link.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 376,500 shares, an increase of 11.0% from the May 31st total of 339,100 shares. Based on an average trading volume of 151,000 shares, the short-interest ratio is currently 2.5 days.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities researchers at HC Wainwright raised their Q4 2024 earnings per share (EPS) estimates for ANI Pharmaceuticals in a research report issued to clients and investors on Wednesday, June 26th. HC Wainwright analyst O. Livnat now anticipat

HC Wainwright upped their target price on ANI Pharmaceuticals from $87.00 to $94.00 and gave the stock a "buy" rating in a research note on Wednesday.

ANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Passes Below 200 Day Moving Average of $61.19

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $63.80, for a total transaction of $15,950.00. Following the transaction, the vice president now directly owns 59,231 shares of the company's stock, valued at $3,778,937.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) was the target of a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 339,100 shares, a growth of 65.9% from the May 15th total of 204,400 shares. Based on an average daily trading volume, of 153,400 shares, the days-to-cover ratio is currently 2.2 days.

Rubric Capital Management LP grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 32.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,125,000 shares of the specialty pharmaceutical company's stoc

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Ori Gutwerg sold 2,985 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $67.00, for a total value of $199,995.00. Following the completion of the transaction, the senior vice president now owns 77,227 shares in the company, valued at approximately $5,174,209. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $64.41, for a total value of $1,288,200.00. Following the completion of the transaction, the senior vice president now owns 213,226 shares in the company, valued at $13,733,886.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Dimensional Fund Advisors LP lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 6.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 591,731 shares of the specialty pharmaceu

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 204,400 shares, a decline of 11.1% from the April 30th total of 229,900 shares. Based on an average daily trading volume, of 159,600 shares, the days-to-cover ratio is currently 1.3 days.

Trexquant Investment LP decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 34.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,484 shares of the speci

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) insider Christopher Mutz sold 2,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $61.61, for a total value of $123,220.00. Following the completion of the sale, the insider now directly owns 83,277 shares in the company, valued at approximately $5,130,695.97. The transaction was disclosed in a document filed with the SEC, which is available through this link.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) COO Muthusamy Shanmugam sold 12,855 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $61.81, for a total transaction of $794,567.55. Following the transaction, the chief operating officer now owns 732,620 shares in the company, valued at $45,283,242.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 10.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 582,428 shares of the specialty pharmaceutical company's stock after acquiring an addition